An observational study in Infertility, Male and Azoospermia, Nonobstructive, sponsored by Peking University Third Hospital. Completed at 1 site in China. Open to male participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-04-11.
Sponsored by Peking University Third Hospital · Observational
Non-obstructive azoospermia (NOA) stands as the most severe form of male infertility. However, due to the diverse nature of testis focal spermatogenesis in NOA patients, accurately assessing the sperm retrieval rate (SRR) becomes challenging. The current study aims to develop and validate a noninvasive evaluation system based on machine learning, which can effectively estimate the SRR for NOA patients. In single-center investigation, NOA patients who underwent microdissection testicular sperm extraction (micro-TESE) were enrolled: (1) 2,438 patients from January 2016 to December 2022, and (2) 174 patients from January 2023 to May 2023 (as an additional validation cohort). The clinical features of participants were used to train, test and validate the machine learning models. Various evaluation metrics including area under the ROC (AUC), accuracy, etc. were used to evaluate the predictive performance of 8 machine learning models.
23 studies on the registry are indexed under Azoospermia, Nonobstructive; 7 are open to participants now.
This study's enrollment of 2,612 is above the median of 94 across 10 observational studies indexed under Azoospermia, Nonobstructive.
Browse Azoospermia, Nonobstructive studies →Peking University Third Hospital is the lead sponsor of 752 studies on the registry; 273 are open to participants now.
Compared within Azoospermia, Nonobstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility, Male. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Nonobstructive azoospermia patients who underwent microdissection testicular sperm extraction at the Reproductive Center of Peking University Third Hospital were respectively enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
2,438 patients diagnosed with NOA were included for model training and validation
Diagnostic Test: Machine learning-based predictive model
174 participants from January 2023 to May 2023 were included as the external validation cohort for online platform
The clinical features of participants were used to train, test and validate the machine learning models. Various evaluation metrics including area under the ROC (AUC), accuracy, etc. were used to evaluate the predictive performance of 8 machine learning models.
SRR of micro-TESE
the sperm retrieval success rate of microdissection testicular sperm extraction
Time frame: At the time after microdissection testicular sperm extraction
Plan to share: No — The raw clinical data are not publicly available. Processed nonsensitive data and analysis code are available from the corresponding author on reasonable request.
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Dec 2022, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital →